A new mixture of three short tripeptides (NMT) was tested alongside Semax in several animal models of brain injury, memory loss, and oxygen deprivation. NMT outperformed Semax on most measures — providing stronger neuroprotection after brain ischemia, better survival under hypoxic conditions, and more effective reversal of drug-induced amnesia. The combination's performance across multiple models positions it as a promising candidate for further development as a neurological drug.
Iasnetsov, V V; Chertorizhskiĭ, E A; Belyĭ, P A; Bespalova, Zh D; Ovchinnikov, M V; Vereshchagina, A O; Ivanov, Iu V; Iasnetsov, Vik V; Kirsanova, S K; Motin, V G